Credibility Changelog

We believe transparency is the foundation of trust. This log documents every significant correction, enhancement, and infrastructure change made to PeptideScholar's content and sourcing practices.

2026-04-26Fix

Removed 47 fabricated PMIDs

Audited the entire peptide database and removed or replaced 47 fabricated PubMed IDs with verified, real citations. Every remaining PMID (76 total) has been cross-checked against the NCBI PubMed database.

2026-04-26Fix

Corrected false regulatory claims

Fixed inaccurate statements including AOD-9604's GRAS status, Sermorelin's discontinuation narrative, and removed 11 fabricated references from blog posts. All clinical-data percentages now match FDA-approved labels.

2026-04-26Deprecate

Deprecated state-level legal content

Added prominent deprecation warnings to all U.S. state legal pages. The content is under review and no longer indexed in the sitemap because statutory interpretations require legal expertise we do not currently provide.

2026-04-26Enhance

Introduced SourcedClaim schema

Migrated all benefits and side-effects from plain strings to SourcedClaim objects, enabling inline citation links and per-claim evidence grades across every peptide page.

2026-04-26Enhance

Launched trust-score badge

Added a dynamic credibility score (0-100) to every peptide detail page. The score weighs evidence level, claim sourcing coverage, reference depth, and grade consistency.

2026-04-26Add

Added 26 verified peptides

Expanded the database from 25 to 51 peptides. New entries include FDA-approved compounds (exenatide, dulaglutide, teriparatide, octreotide, pramlintide, setmelanotide, etc.) and research peptides explicitly marked with evidence level D and 'no human data' disclaimers.

2026-04-26Enhance

Bulk evidence-grade assignment

Applied default evidence grades (A-D) to all 440+ individual claims based on each peptide's overall evidence level, ensuring consistent transparency about claim reliability.

Have you found an error or want to suggest a correction? Contact us.